Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Stock
Key stats
- Market cap
- $6.18B
- Price / Earnings ratio
- -6.8x
- EPS (TTM)
- -$15.23
- Volume
- Loading
- 52-week high
- $130.00
- 52-week low
- $63.23
Source: third-party data provider, as of November 13, 2026
Compare with MIRM
Recent news

Mirum Pharmaceuticals Q3 Earnings Call Highlights
Mirum Pharmaceuticals Q3 Earnings Call Highlights
MIRM

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
MIRM

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
MIRM

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
MIRM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 61.85
- MACD 12/26/9
- 2.01
- EMA 9 of MACD
- 0.63
- MACD histogram
- 1.37
- SMA 50
- $89.05
- Price above SMA 50
- EMA 50
- $90.27
- Price above EMA 50
- SMA 200
- $98.49
- Price below SMA 200
- EMA 200
- $92.81
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 11 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Mirum Pharmaceuticals Q3 Earnings Call Highlights
Mirum Pharmaceuticals Q3 Earnings Call Highlights
MIRM

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
MIRM

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
MIRM

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
MIRM

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
MIRM

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
MIRM

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
MIRM

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
MIRM

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Mirum Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher Peetz | CEO & Director | 1979 |
| Mr. Peter Radovich M.B.A., Ph.D. | COO & President | 1978 |
| Mr. Eric H. Bjerkholt M.B.A., M.S. | Chief Financial Officer | 1960 |
| Dr. Joanne M. J. Quan M.D. | Chief Medical Officer | 1964 |
| Dr. Jean-Luc Girardet Ph.D. | Chief Technical Officer | — |
| Mr. Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | — |
| Mr. Douglas T. Sheehy J.D. | Chief Legal Officer & Secretary | 1967 |
| Meredith Kiernan | Senior Director of Global Corporate Communications | — |
| Ms. Erin Campany | Chief People Officer | 1968 |
| Ms. Lara Longpre MBA, MSC | Chief Development Officer | 1970 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 61.85
- MACD 12/26/9
- 2.01
- EMA 9 of MACD
- 0.63
- MACD histogram
- 1.37
- SMA 50
- $89.05
- Price above SMA 50
- EMA 50
- $90.27
- Price above EMA 50
- SMA 200
- $98.49
- Price below SMA 200
- EMA 200
- $92.81
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
11 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $130.00
- Average
- $158.82
- High
- $202.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.1 | +15.9 | ||||||||||
| 2022 | +16.4 | +25.1 | +3.2 | +2.4 | -4.0 | -18.2 | +25.6 | +8.1 | -17.3 | +4.3 | -19.2 | +6.7 |
| 2023 | +21.8 | -1.5 | +1.4 | +7.4 | -2.8 | -0.9 | +0.4 | +5.8 | +19.5 | -6.4 | +12.8 | -7.8 |
| 2024 | -11.9 | +8.0 | -14.2 | -1.3 | -6.6 | +34.9 | +18.7 | +7.4 | -5.6 | -4.1 | +14.4 | -10.5 |
| 2025 | +16.3 | -2.1 | -2.0 | -1.3 | +2.4 | +10.7 | +6.8 | +42.0 | -1.4 | -0.5 | +3.1 | +12.8 |
| 2026 | +32.2 | -11.1 | +2.5 | +2.8 | +5.1 | +21.5 | -12.0 | -6.3 | -13.1 | +1.3 | +10.3 |



